EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Helicobacter pylori Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort

Encarnación Fernández-Antón iD, Olga P Nyssen iD, Gabriela Alonso-Martínez, Pablo Parra iD, Miguel Gil, Javier P Gisbert iD, Francisco J de Abajo

Helicobacter · 2026

DOI: 10.1111/hel.70122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, 2026. Verfasst von Encarnación Fernández-Antón und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain. Hauptthemen laut MEDLINE: Helicobacter Infections, Primary Health Care, Anti-Bacterial Agents, Proton Pump Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Teófilo Hernando, European Helicobacter and Microbiota Study Group, Spanish Association of Gastroenterology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Helicobacter pylori is a common infection primarily managed in primary care. Assessing real‐world practices and guideline adherence is crucial for treatment optimisation. The study aims to assess current H. pylori management strategies using data from BIFAP, a Spanish primary care database. Materials and Methods Cohort study including patients aged ≥ 18 with recorded H. pylori infection (2003–2023) and corresponding treatment prescriptions. Infection cases were identified using ICD‐9/10 and SNOMED‐CT codes. Treatment patterns were based on Spanish and European guidelines. First‐line treatment prescriptions were compared between primary (BIFAP) and specialized (European Registry, Hp‐EuReg) care.

Results

A total of 211,972 H. pylori ‐ infected subjects were identified. Over the study period (20 years), the predominant first‐line treatments were: bismuth quadruple therapy including a proton‐pump inhibitor (PPI) plus a single capsule containing bismuth‐tetracycline‐metronidazole (36%); PPI + clarithromycin‐amoxicillin (30%); and PPI + clarithromycin‐amoxicillin‐metronidazole (26%). Single‐capsule bismuth quadruple therapy was the most common in patients aged 18–64 and those with obesity, chronic kidney disease, or smokers, while PPI + clarithromycin‐amoxicillin was more common in those aged ≥ 65 or with peptic ulcers. Since 2013, PPI + clarithromycin‐amoxicillin use by general practitioners and gastroenterologists decreased, though it remained above 10% in primary care at study end. PPI + clarithromycin‐amoxicillin‐metronidazole increased since 2015, with higher use in specialized care (40%) vs. primary care (30%). In 2023, single‐capsule bismuth quadruple therapy was the most prescribed regimen in both settings, accounting for ~60% of prescriptions.

Conclusions

Primary care H. pylori treatments are varied, with single‐capsule bismuth quadruple therapy most prescribed. Guidelines are followed, but adoption is slower in primary than in specialized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsPrimary Health CareAnti-Bacterial AgentsProton Pump InhibitorsRegistriesHelicobacter pyloriSpainHumansMaleFemaleYoung AdultAdultMiddle AgedAgedAged, 80 and overDrug Therapy, CombinationPractice Guidelines as TopicDrug Combinations

Stichwörter der Autor:innen

H. pyloribismutheradication treatmentprimary‐specialized care

Substanzen

Anti-Bacterial AgentsProton Pump InhibitorsDrug Combinations

Autor:innen und Institutionen

  • Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain.
  • Teófilo Hernando Foundation, Madrid, Spain.
  • Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de…
  • BIFAP Unit, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines Agency Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de M…
  • Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain.

ORCID-Profile: Encarnación Fernández-Antón, Olga P Nyssen, Pablo Parra, Javier P Gisbert

Förderung

  • Fundación Teófilo Hernando
  • European Helicobacter and Microbiota Study Group
  • Spanish Association of Gastroenterology
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
  • European Union programme HORIZON
  • UK Research and Innovation
  • European Union programme EU4Health
  • Diasorin

Zitieren

APA

Fernández-Antón, E., Nyssen, O. P., Alonso-Martínez, G., Parra, P., Gil, M., Gisbert, J. P., & de Abajo, F. J. (2026). Helicobacter pylori Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort. Helicobacter. https://doi.org/10.1111/hel.70122

Vancouver

Fernández-Antón E, Nyssen OP, Alonso-Martínez G, Parra P, Gil M, Gisbert JP, et al. Helicobacter pylori Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort. Helicobacter. 2026. doi:10.1111/hel.70122

BibTeX
@article{FernndezAntn2026,
  author = {Fernández-Antón, Encarnación and Nyssen, Olga P and Alonso-Martínez, Gabriela and Parra, Pablo and Gil, Miguel and Gisbert, Javier P and de Abajo, Francisco J},
  title = {Helicobacter pylori Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70122}
}
Kostenlos starten →